Sympathoinhibition as a preferred second line treatment of obesity related hypertension

Project Details

StatusActive
Effective start/end date1/03/2029/02/24

Funding

  • Abbott Products Operations AG: A$231,010.00
  • Abbott Products Operations AG: A$231,000.00
  • Abbott Products Operations AG: A$147,000.00
  • Abbott Products Operations AG: A$37,000.00
  • Abbott Products Operations AG: A$37,000.00